SCHEMBL20939719

SCHEMBL20939719

COCCn1nc2c(c1N)CCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.35
CYP1A2 P05177 1/20 0.35
GAA P10253 1/20 0.35
NTRK1 P04629 6/20 0.34
EHMT2 Q96KQ7 1/20 0.33
MAPT P10636 2/20 0.33
MPO P05164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PSEN1 P49768 2/20 0.32
PSEN2 P49810 2/20 0.32
APH1B Q8WW43 2/20 0.32
NCSTN Q92542 2/20 0.32
APH1A Q96BI3 2/20 0.32
PSENEN Q9NZ42 2/20 0.32
MEN1 O00255 1/20 0.32
ACHE P22303 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
BPTF Q12830 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20939185 0.81 POLQ (0.41) POLBCYP1A2GAANTRK1EHMT2
SCHEMBL11702724 0.77 HTT (0.37) POLBCYP1A2GAAMAPTTDP1
SCHEMBL17045400 0.77 ACHE (0.38) POLBCYP1A2GAAMAPTTDP1
SCHEMBL20939720 0.75 BRD4 (0.33) GAAMPOADORA2BALDH1A1
SCHEMBL11743978 0.73 POLB (0.32) POLBCYP1A2GAAMAPTL3MBTL1
SCHEMBL12073002 0.73 POLB (0.40) POLBCYP1A2GAAMAPTTDP1
SCHEMBL12335143 0.72 POLB (0.52) POLBCYP1A2GAAMAPTTDP1
SCHEMBL693194 0.70 MPO (0.38) GAAMPOTDP1KDM4EALDH1A1
SCHEMBL17045386 0.69 ACHE (0.34) POLBCYP1A2GAANTRK1PSEN1
SCHEMBL5067152 0.69 POLB (0.57) POLBCYP1A2GAAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186589-B2 Cyanoindoline derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-11-30 US disclosed
US-20210032267-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-04 US disclosed
EP-3478673-B1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-16 EP disclosed
US-20190119299-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032267-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS MAP3K14, NFKBIA, MAP3K15 POLB 1123/4885CYP1A2 3160/4885GAA 2591/4885
US-20190119299-A1 CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS NFKBIA, IKBKG, IKBKB POLB 826/4885CYP1A2 3310/4885GAA 2969/4885
US-11186589-B2 Cyanoindoline derivatives as NIK inhibitors MAP3K14, NFKBIA, MAP3K15 POLB 1123/4885CYP1A2 3160/4885GAA 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.